Vertex Pharmaceuticals Incorporated (VRTX)
- Previous Close
404.91 - Open
404.50 - Bid 400.51 x 100
- Ask 400.91 x 100
- Day's Range
399.29 - 406.83 - 52 Week Range
320.01 - 448.40 - Volume
793,310 - Avg. Volume
1,205,167 - Market Cap (intraday)
103.58B - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
28.81 - EPS (TTM)
13.91 - Earnings Date May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
466.14
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
www.vrtx.comRecent News: VRTX
Performance Overview: VRTX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRTX
Valuation Measures
Market Cap
103.58B
Enterprise Value
93.17B
Trailing P/E
28.85
Forward P/E
24.57
PEG Ratio (5yr expected)
0.54
Price/Sales (ttm)
10.58
Price/Book (mrq)
5.89
Enterprise Value/Revenue
9.44
Enterprise Value/EBITDA
20.23
Financial Highlights
Profitability and Income Statement
Profit Margin
36.68%
Return on Assets (ttm)
13.17%
Return on Equity (ttm)
22.99%
Revenue (ttm)
9.87B
Net Income Avi to Common (ttm)
3.62B
Diluted EPS (ttm)
13.91
Balance Sheet and Cash Flow
Total Cash (mrq)
11.22B
Total Debt/Equity (mrq)
4.60%
Levered Free Cash Flow (ttm)
3.51B
Research Analysis: VRTX
Company Insights: VRTX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: VRTX
Analyst Report: Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
RatingPrice TargetAnalyst Report: Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals develops therapies to address cystic fibrosis and other diseases. The company was founded in 1989 in Cambridge, Massachusetts and has 4,800 employees. It has research programs and facilities in the U.S., the UK, and Canada. The shares are a component of the S&P 500.
RatingPrice TargetMarket Digest: CB, CMCSA, EFX, HES, MAS, NFG, PEP, SPH, VRTX, XYL
Monday Tee Up: Is Inflation Still Tracking Lower?
Analyst Report: Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
RatingPrice Target